NERV — Minerva Neurosciences Share News
0.000.00%
Last trade - 00:00Brief: Minerva Neurosciences Inc Files For Resale Of Up To 2 Mln Shares - SEC Filing
Brief: Minerva Neurosciences Q2 Basic EPS USD -1.12
U.S. STOCKS ON THE MOVE-Louisiana-Pacific, Jefferies Financial Group, Beazer Homes
U.S. STOCKS ON THE MOVE-Netflix, Genprex, Joby Aviation
U.S. STOCKS ON THE MOVE-Cognition Therapeutics, Pinterest, Minerva Neurosciences
Minerva Neurosciences surges on $20 mln premium equity raise
Brief: Minerva Neurosciences Announces $20 Million In Private Placement Priced At A Premium To Market
Brief: Minerva Neurosciences Said It Got Written Notice From Nasdaq Informing Co It Has Regained Compliance With Nasdaq Listing Rule 5550 On June 16
Brief: Minerva Neurosciences Receives Second Written Notice From Nasdaq
Minerva Neurosciences Inc reports results for the quarter ended in March - Earnings Summary
Brief: Minerva Neurosciences Reports 2023 First Quarter Financial Results And Business Updates
Minerva Neurosciences Inc expected to post a loss of $1.63 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-First Citizens BancShares, Sarepta, Celsius Holdings
U.S. STOCKS ON THE MOVE-Taboola, US banks, Copper miners
Minerva Neurosciences rises as FDA accepts marketing application for schizophrenia drug
Brief: Minerva Neurosciences Announces Update On New Drug Application (NDA) For Roluperidone
U.S. STOCKS ON THE MOVE-US banks, Biomea Fusion, Tutor Perini
U.S. STOCKS ON THE MOVE-Minerva Neurosciences, Midwest Holding, Global Payments
Minerva Neurosciences up on filing marketing application for mental disorder drug